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Abstract 
Post-transplant lymphoproliferative disorders 
(PTLDs) are serious, life-threatening complications 
of transplantation, which represent a heterogeneous 
group of lymphoproliferative diseases and show a 
spectrum of clinical, morphologic, and molecular 
genetic features ranging from reactive polyclonal 
lesions to frank lymphomas. Classical Hodgkin 
lymphoma (CHL) is the least common form of 
PTLD, which is almost always EBV-positive and 
should fufill the criteria for CHL. 
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Disease 
The term "post-transplant lymphoproliferative 
disorder" or disease (PTLD) was first introduced in 
1984 by Starzl ( Starzl et al. 1984) .PTLDs are 
serious, life-threatening complications of solid-
organ transplantation (SOT) and bone marrow 
transplantation, and are associated with high 
mortality. PTLDs represent a heterogeneous group 
of lymphoproliferative diseases, which show a 
spectrum of clinical, morphologic, and molecular 
genetic features ranging from reactive polyclonal 
lesions to frank lymphomas. 
PTLDs are classified into early lesions, 
polymorphic, monomorphic, and classical Hodgkin's 
lymphoma-like PTLD. 
P CHL type PTLD occurs in the post-transplant 
setting, most often in renal transplant patients, 
composed of variable numbers of HRS cells 
admixed with a rich inflammatory background. The 
composition of the reactive cellular infiltrate varies 
according to the histological subtype (Swerdlow, et 
al ,2008. Mucha, et al. 2010.). 
Phenotype/cell stem origin 
The majority (>90%) of PTLD in solid organ 
recipients are of host origin and only a minority of 
donor origin. Donor origin PTLD appear to be most 
common in liver and lung allograft recipients, and 
frequently involve the allograft. In contrast, the 
majority of PTLD in bone marrow (BM) allograft 
recipients are of donor origin, as would be expected, 
since successful engraftment results in an immune 
system that is nearly exclusively of donor origin 
(Chadbum, et al ,1995. Swerdlow, et al ,2008). 
Phenotypically, CHL type PTLD cases show 
CD30+,CD15+,CD20- in HRS cells, but some cases 
are CD15-.Because RS like cells may be seen in 
early, polymorphic and some monomorphic PTLD, 
the diagnosis of CHL must be distinguished from 
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Hodgkin like lesions, in which the EBV+ RS like 
cells are CD45+, CD30+, CD15-, CD20+ and small 
to intermediate-sized EBV+ lymphoid cells can be 
seen as well (werdlow, et al ,2008. Pitman et al,2006. 
Ranfanathan, et al, 2004). 
Epidemiology 
The incidence of PTLD ranges from 1-3 % in renal 
to 5-20 % in lung and intestinal transplantation, 
related to the type of transplanted organ, intensity of 
IS, age, and viral infection, etc. ( Opelz, 2003. 
Opelz,1993). In contrast, the incidence of PTLD 
after BMT is about 1.0 % for recipients from HLA-
compatible related donors (lower than that of SOT), 
but in up to 25 % for high-risk patients (Curtis, 
1999). However, the field has evolved during the last 
decade. Hoegh-Petersen et al. found a frequency of 
8.1 % among 307 allo-HSCT recipients who had also 
received ATG-based conditioning. Kamani et al. 
found an overall incidence of 2.3 % for post-
transplant malignancy (most of which were PTLD) 
in patients receiving such transplant for primary 
immunodeficiency disorders. The highest subgroup, 
those patients with Wiskott-Aldrich syndrome, had a 
3.3 % frequency. 
In our hospital, it is 1.5 % (9/585) from August 2002 
to October 2006 and about 1 % (9/857) from 
November 2006 to November 2009 after allo-HSCT, 
respectively. The incidence of PTLD was higher in 
mismatched or unrelated HSCT group than that of 
conventional one, 3.4 % (7/208), 2.3 % (1/44) versus 
0/323. It was also higher in patients with 
conditioning regimen including ATG than those 
without, 3.4 % (9/262) vs. 0/323. CHL type PTLD is 
the least common major form of PTLD (Swerdlow, 
et al ,2008. Chen, et al ,2013). 
Clinics 
The clinical features of PTLD differ from those of 
lymphomas observed in the general population. 
Symptoms may be mild, such as fever, 
mononucleosis-like syndrome, lymphadenopathy, 
recurrent infections or severe organ dysfunction. The 
variable manifestation of PTLD depends on many 
factors, such as the type of transplanted organ or IS 
used, histopathology and time elapsed since 
transplantation. The first year after transplantation is 
important, in lung recipients, more than 50 % of all 
PTLDs develop during the first post-transplant year. 
Our data showed that 88.2 % of patients (15/17) were 
diagnosed within 7 months after transplantation (1.5-
7 months), and the median interval after 
transplantation to the diagnosis was 2.5 months 
(mean 4.7 months, range 1.5-19 months), shorter 
than that of SOT. The frequent sites of PTLD include 
GI (jejunum more often than colon), lymph nodes, 
and central nervous system, different from type to 
type of transplantation (Opelz, et al, 2003. 
Swerdlow, et al ,2008). 
Pathology 
CHL type PTLD is characterized by effacement of 
the architecture and composed of variable numbers 
of HRS cells admixed with a rich inflammatory 
background. The composition of the reactive cellular 
infiltrate varies according to the histological 
subtype. The diagnosis of CHL must be 
distinguished from Hodgkin like lesions, in which 
the EBV+ RS like cells are CD45+, CD30+, CD15-, 
CD20+ and small to intermediate-sized EBV+ 
lymphoid cells can be seen as well, especially from 
polymorphic PTLD, and the overall morphologic 
features should be depended on. 
There are four histologic subtypes of classical 
Hodgkin lymphomas,, i.e. nodular sclerosis cHL, 
mixed cellularity cHL, lymphocyte-rich cHL, and 
lymphocyte depleted cHL, according to their 
cellularity and background. MC subtype is most 
common. 
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Figure 1.  Hodgkin type PTLD. Effacement of the architecture and HRS cells surrounded by small lymphocytes, 
neutrophils and eosinophils ( HE stain). 
 
Figure 2.  HRS cells are positive for CD30. 
 
Classical Hodgkin lymphoma type PTLD  
 
 
Atlas Genet Cytogenet Oncol Haematol. 2018; 22(3): 107 
 
 
 
Figure 3.  Some HRS cells are positive for CD15. 
 
 
Figure 4.  HRS cells are positive for EBER (in situ hybridization). 
Treatment 
There is no consensus on the optimal treatment of 
PTLD. It is generally agreed that three major 
strategies should be applied: restoration of the 
recipient's immunity (to limit the EBV infection), 
elimination EBV and removal of neoplastic B cells. 
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Reduction of IS or even withdrawal remains the first-
line treatment. With reduction of 
immunosuppression, virtually all early lesions 
regress and generally show good prognosis, whereas 
half of P-PTLD regress and some will progress, the 
majority of M-PTLDs do not regress. DLI was 
effectively used in EBV-associated PTLD after 
mismatched/haploidentical haematopoietic stem cell 
transplantation (HSCT). Patients with lymph node 
localization have a relatively good outcome, and 
disseminated disease in contrast has a poor prognosis 
(Mucha, et al, 2010. Xu, et al, 2010). 
Staging of CHL type PTLD determines the mode of 
therapy. 
Prognosis 
The prognosis of PTLD is poor. The treatment of 
rejection episodes with OKT3 or ATG enhances the 
PTLD risk in patients who did not receive antibody 
induction, rejection therapy with OKT3 or ATG adds 
to the already increased lymphoma risk HLA 
matching is also a risk factor in the pathogenesis of 
PTLD, and HLA-B or HLA-DR mismatches 
especially seem to be critical. The number of HLA  
mismatches parallels with an increased risk of PTLD 
(Opelz, et al, 2003. Opelz, et al, 2010). 
Both clinical and laboratory parameters of CHL type 
PTLD are relevant to prognosis. histologic subtype 
is less important as a predictive factor (Allemani, et 
al, 2006). 
Genetics 
Note 
HRS cells contain clonal immunoglobulin (IG) gene 
rearrangements in more than 98% of cases, and 
clonal T cell receptor gene rearrangements in rare 
cases. Some studies indicate that HRS cells of B-cell 
lineage are derived from a germinal centre B cell 
(Swerdlow, et al ,2008. Melzner ,et al,2006). 
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